Cargando…
Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the repo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046001/ https://www.ncbi.nlm.nih.gov/pubmed/36979848 http://dx.doi.org/10.3390/biomedicines11030869 |
_version_ | 1785013556535623680 |
---|---|
author | Katsuyama, Hisayuki Hakoshima, Mariko Umeyama, Shohei Iida, Sakura Adachi, Hiroki Yanai, Hidekatsu |
author_facet | Katsuyama, Hisayuki Hakoshima, Mariko Umeyama, Shohei Iida, Sakura Adachi, Hiroki Yanai, Hidekatsu |
author_sort | Katsuyama, Hisayuki |
collection | PubMed |
description | The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the reports of real-world efficacy on metabolic parameters in Japanese patients with type 2 diabetes (T2DM) are limited. This study aimed to examine the real-world efficacy of GLP-1RA dulaglutide on metabolic parameters in Japanese patients with T2DM. We retrospectively selected patients with T2DM who had been prescribed dulaglutide continuously for 12 months or longer between September 2015 and December 2020 and compared metabolic parameters at baseline with the data at 12 months after the start of dulaglutide. One hundred twenty-one patients were enrolled in this study. The 12-month dulaglutide treatment reduced body weight by 1.7 kg and hemoglobin A1c by 1.1%. Significant improvements were also observed in serum high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C. The change in HbA1c during dulaglutide treatment was significantly correlated with the changes in HDL-C (R = −0.236, p = 0.013), LDL-C (R = 0.377, p = 0.005) and non-HDL-C (R = 0.415, p < 0.001). The improvements in HbA1c, HDL-C, TG and non-HDL-C were greater in patients concurrently treated with SGLT2 inhibitors (SGLT2is) at baseline. In conclusion, the treatment with dulaglutide has beneficial effects on multiple CV risk factors in Japanese patients with T2DM. |
format | Online Article Text |
id | pubmed-10046001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100460012023-03-29 Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Katsuyama, Hisayuki Hakoshima, Mariko Umeyama, Shohei Iida, Sakura Adachi, Hiroki Yanai, Hidekatsu Biomedicines Article The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the reports of real-world efficacy on metabolic parameters in Japanese patients with type 2 diabetes (T2DM) are limited. This study aimed to examine the real-world efficacy of GLP-1RA dulaglutide on metabolic parameters in Japanese patients with T2DM. We retrospectively selected patients with T2DM who had been prescribed dulaglutide continuously for 12 months or longer between September 2015 and December 2020 and compared metabolic parameters at baseline with the data at 12 months after the start of dulaglutide. One hundred twenty-one patients were enrolled in this study. The 12-month dulaglutide treatment reduced body weight by 1.7 kg and hemoglobin A1c by 1.1%. Significant improvements were also observed in serum high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C. The change in HbA1c during dulaglutide treatment was significantly correlated with the changes in HDL-C (R = −0.236, p = 0.013), LDL-C (R = 0.377, p = 0.005) and non-HDL-C (R = 0.415, p < 0.001). The improvements in HbA1c, HDL-C, TG and non-HDL-C were greater in patients concurrently treated with SGLT2 inhibitors (SGLT2is) at baseline. In conclusion, the treatment with dulaglutide has beneficial effects on multiple CV risk factors in Japanese patients with T2DM. MDPI 2023-03-13 /pmc/articles/PMC10046001/ /pubmed/36979848 http://dx.doi.org/10.3390/biomedicines11030869 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Katsuyama, Hisayuki Hakoshima, Mariko Umeyama, Shohei Iida, Sakura Adachi, Hiroki Yanai, Hidekatsu Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study |
title | Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study |
title_full | Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study |
title_fullStr | Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study |
title_full_unstemmed | Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study |
title_short | Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study |
title_sort | real-world efficacy of glucagon-like peptide-1 (glp-1) receptor agonist, dulaglutide, on metabolic parameters in japanese patients with type 2 diabetes: a retrospective longitudinal study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046001/ https://www.ncbi.nlm.nih.gov/pubmed/36979848 http://dx.doi.org/10.3390/biomedicines11030869 |
work_keys_str_mv | AT katsuyamahisayuki realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy AT hakoshimamariko realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy AT umeyamashohei realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy AT iidasakura realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy AT adachihiroki realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy AT yanaihidekatsu realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy |